{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:47:55Z","timestamp":1792795675404,"version":"4.5.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>The effects of Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) on lipid profiles have been observed in chronic hepatitis B (CHB) treatment. However, the metabolic features and their impact on cardiovascular risk remain unclear. We conducted a systematic review and meta-analysis to evaluate these effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched for studies from four major databases (PubMed, Web of Science, EMBASE, and the Cochrane Library) that reported the effects of TDF or TAF on metabolism and cardiovascular disease risk. The changes in metabolic parameters and 10-year atherosclerotic cardiovascular disease (ASCVD) risk were compared with baseline in the TDF and TAF treatment groups. Extracted data were analyzed with the random-effects model or the fixed-effects model. Potential sources of heterogeneity were investigated using sensitivity and subgroup analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 19 studies including 19,396 CHB patients (12,067 in TDF\u2010only group, 5,423 in TAF\u2010only group, and 1906 in TDF-switched group) were included in this meta-analysis. We found that both TAF and TDF treatment mildly increase the 10-year ASCVD risk. The TAF treatment showed significant increases in body weight, with no significant effects were observed on lipid levels or blood glucose. While TDF treatment has a lipid-lowering effect and caused weight loss. Subanalyses emphasized the impact of changing antiviral treatment strategies on metabolism. We found an increased risk of dyslipidemia and body weight gain after switching from TDF to TAF treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although TAF and TDF treatments exhibit different metabolic characteristics, both mildly increase the risk of cardiovascular disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p>identifier CRD42024595452<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1604972","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T08:34:18Z","timestamp":1751272458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Metabolic effects and cardiovascular disease risks of TDF or TAF in patients with chronic hepatitis B: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuan-Hai","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Lu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5812\/hepatmon.118721","article-title":"Comparison of tenofovir alafenamide and entecavir therapy in patients with chronic hepatitis B initially treated with tenofovir disoproxil: a retrospective observational survey","volume":"21","author":"Akdemir Kalkan","year":"2022","journal-title":"Hepat. Mon."},{"key":"B3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"III8","DOI":"10.1161\/01.CIR.0000131512.50667.46","article-title":"HDL cholesterol and protective factors in atherosclerosis","volume":"109","author":"Assmann","year":"2004","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2020.12.013","article-title":"New cardiovascular prevention guidelines: how to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?","volume":"319","author":"Atar","year":"2021","journal-title":"Atherosclerosis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/cid\/ciac949","article-title":"Weight and metabolic changes after switching from tenofovir alafenamide\/emtricitabine (FTC)+Dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)\/FTC + DTG, and TDF\/FTC\/Efavirenz to TDF\/Lamivudine\/DTG","volume":"76","author":"Bosch","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","article-title":"Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate","volume":"20","author":"Byun","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12872-019-1228-7","article-title":"The ratio of total cholesterol to high density lipoprotein cholesterol and myocardial infarction in Women\u2019s health in the lund area (WHILA): a 17-year follow-up cohort study","volume":"19","author":"Calling","year":"2019","journal-title":"BMC Cardiovasc Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e31980","DOI":"10.1097\/MD.0000000000031980","article-title":"Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: a cross-sectional survey","volume":"101","author":"Chen","year":"2022","journal-title":"Med. Baltim."},{"key":"B11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/apt.17765","article-title":"Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B","volume":"59","author":"Cheng","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B12","unstructured":"Cochrane Handbook for Systematic reviews of interventions\n          \n          \n          2025"},{"key":"B13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"106151","DOI":"10.1016\/j.antiviral.2025.106151","article-title":"Tenofovir alafenamide promotes weight gain and impairs fatty acid metabolism-related signaling pathways in visceral fat tissue compared to tenofovir disoproxil fumarate","volume":"237","author":"Dulion","year":"2025","journal-title":"Antivir. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.2337\/dc12-0336","article-title":"Metabolic syndrome and risk of cancer: a systematic review and meta-analysis","volume":"35","author":"Esposito","year":"2012","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/apt.17764","article-title":"Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks","volume":"59","author":"Fung","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1464-5491.2004.01341.x","article-title":"Usefulness of total cholesterol\/HDL\u2010cholesterol ratio in the management of diabetic dyslipidaemia","volume":"22","author":"Gimeno\u2010Orna","year":"2005","journal-title":"Diabet. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology\/american heart association task force on practice guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/american heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S858","DOI":"10.1016\/S0168-8278(22)02013-X","article-title":"Real life efficacy, renal and lipid profile data of tenofovir alafenamide in switched chronic hepatitis B patients","volume":"77","author":"Guner","year":"2022","journal-title":"J. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/QAI.0b013e3182a60f7d","article-title":"HIV\u2013HBV coinfection in Southern Africa and the effect of Lamivudine- Versus tenofovir-containing cART on HBV outcomes","volume":"64","author":"Hamers","year":"2013","journal-title":"JAIDS J. Acquir Immune Defic. Syndr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3350\/cmh.2023.0328","article-title":"Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide","volume":"30","author":"Hong","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"ofz472","DOI":"10.1093\/ofid\/ofz472","article-title":"Atherosclerotic cardiovascular disease risk profile of tenofovir alafenamide Versus tenofovir disoproxil fumarate","volume":"7","author":"Huhn","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s12072-023-10528-7","article-title":"Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis","volume":"17","author":"Hwang","year":"2023","journal-title":"Hepatol. Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology\/american heart association task force on practice guidelines and the obesity society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3350\/cmh.2021.0314","article-title":"Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis","volume":"28","author":"Jeong","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14744\/hf.2022.2022.0043","article-title":"First year real life experience with tenofovir alafenamide fumarate: the pythagorean cohort","volume":"4","author":"Karasahin","year":"2023","journal-title":"Hepatol. Forum"},{"key":"B29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1089\/apc.2019.0236","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide significantly worsens the lipid profile in a real-world setting","volume":"33","author":"Kauppinen","year":"2019","journal-title":"AIDS Patient Care STDs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"964","DOI":"10.4254\/wjh.v15.i8.964","article-title":"Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients","volume":"15","author":"Lai","year":"2023","journal-title":"World J. Hepatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/liv.15261","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment\u2010na\u00efve chronic hepatitis B","volume":"42","author":"Lim","year":"2022","journal-title":"Liver Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat. Methods Med. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jacl.2022.06.003","article-title":"Coronary computed tomography angiography evaluation of plaque morphology and its relationship to HDL and total cholesterol to HDL ratio","volume":"16","author":"Manubolu","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/apt.17107","article-title":"Switching to tenofovir alafenamide for nucleos(t)ide analogue\u2010experienced patients with chronic hepatitis B: week 144 results from a real\u2010world, multi\u2010centre cohort study","volume":"56","author":"Ogawa","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B35","unstructured":"The Newcastle-Ottawa scale (NOS) for assessing the quality of non-randomised studies in meta-analyses\n          \n          \n          2025"},{"key":"B36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/cid\/civ296","article-title":"The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial","volume":"61","author":"Santos","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"S189","DOI":"10.1097\/QAD.0000000000003083","article-title":"Is tenofovir disoproxil fumarate associated with weight loss?","volume":"35","author":"Shah","year":"2021","journal-title":"AIDS"},{"key":"B38","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"7","author":"Sheena","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e29760","DOI":"10.1002\/jmv.29760","article-title":"Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B","volume":"96","author":"Shin","year":"2024","journal-title":"J. Med. Virol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0261760","DOI":"10.1371\/journal.pone.0261760","article-title":"Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B","volume":"17","author":"Suzuki","year":"2022","journal-title":"PLOS ONE"},{"key":"B41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3350\/cmh.2022.0084","article-title":"KASL clinical practice guidelines for management of chronic hepatitis B","volume":"28","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00228-023-03616-y","article-title":"Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis","volume":"80","author":"Tong","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/apt.15575","article-title":"Systematic review: chronic viral hepatitis and metabolic derangement","volume":"51","author":"Wang","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/03007995.2016.1264932","article-title":"Benefits of long-term therapy with nucleos(t)ide analogues in treatment-na\u00efve patients with chronic hepatitis B","volume":"33","author":"Wei","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"B46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2011.09.013","article-title":"Hepatitis B virus infection and fatty liver in the general population","volume":"56","author":"Wong","year":"2012","journal-title":"J. Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jfma.2021.09.009","article-title":"Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide","volume":"121","author":"Yeh","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1002\/jmv.27977","article-title":"Real\u2010life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients","volume":"94","author":"Zhang","year":"2022","journal-title":"J. Med. Virol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"13596535221082399","DOI":"10.1177\/13596535221082399","article-title":"Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: a prospective real-world clinical study","volume":"27","author":"Zhang","year":"2022","journal-title":"Antivir. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1399665","DOI":"10.3389\/fmed.2024.1399665","article-title":"Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients","volume":"11","author":"Zhao","year":"2024","journal-title":"Front. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1604972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T08:34:19Z","timestamp":1751272459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1604972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":50,"alternative-id":["10.3389\/fphar.2025.1604972"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1604972","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"1604972"}}